Skip to main content
. 2014 Feb 3;2014:813067. doi: 10.1155/2014/813067

Figure 6.

Figure 6

In vivo validation on a favorable prognostic signature in subsets of ER(+) IDCs and 181 IDCs. Panel A presents the heatmap displaying forty-one prognostic relevant probes, which are predicted to show the consensus expression dynamics in both 90A cohort and 181A cohort. These 41 probes are part of the most relevant transcriptional activities of both MYB and ARNT2 in a subset of ER(+) IDCs (a) or in the subset of 181 IDCs predominantly containing ER(+) subtype (b). Panel B demonstrates that the Kaplan-Meier survival curves significantly show the difference in clinical outcomes when comparing subcohorts A(15A)/B(8A) (c) and subcohorts C(16A)/D(35A) (d), respectively. It indicates forty-one probes to be the favorable prognostic signature driven by MYB in coupling with ARNT2. The tumor samples in subcohorts A/C have relatively higher mRNA levels of MYB and ARNT2 than those in subcohorts B/D. However, the tumor samples in subcohorts A/C have relatively lower mRNA levels of MYBL1 and MYBL2 than those in subcohorts B/D. “NT” stands for non-tumor component.